Document Type

Journal Article

Authors

Shuaijian Ni, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Zhenjian Zhuo, School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong
Yuefei Pan, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Hong Kong
Yuanyuan Yu, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Fangfei Li, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Jin Liu, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Luyao Wang, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Xiaoqu Wu, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Dijie Li, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Youyang Wan, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Lihe Zhang, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
Zhenjun Yang, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing
Bao-Ting Zhang, School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong
Aiping Lu, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong
Ge Zhang, Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong

Department/Unit

School of Chinese Medicine

Language

English

Abstract

Aptamers are oligonucleotide sequences with a length of about 25–80 bases which have abilities to bind to specific target molecules that rival those of monoclonal antibodies. They are attracting great attention in diverse clinical translations on account of their various advantages, including prolonged storage life, little batch-to-batch differences, very low immunogenicity, and feasibility of chemical modifications for enhancing stability, prolonging the half-life in serum, and targeted delivery. In this Review, we demonstrate the emerging aptamer discovery technologies in developing advanced techniques for producing aptamers with high performance consistently and efficiently as well as requiring less cost and resources but offering a great chance of success. Further, the diverse modifications of aptamers for therapeutic applications including therapeutic agents, aptamer–drug conjugates, and targeted delivery materials are comprehensively summarized.

Keywords

aptamer, microfluidic SELEX, long-acting modification, aptamer−drug conjugate (ApDC), targeted delivery materials, nanoparticle, therapeutic application

Publication Date

6-30-2020

Source Publication Title

Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications

Publisher

American Chemical Society

DOI

10.1021/acsami.0c05750

Link to Publisher's Edition

https://doi.org/10.1021/acsami.0c05750

ISSN (print)

19448244

ISSN (electronic)

19448252

Comments

This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Share

COinS